Important changes to the Patented Medicine Prices Review Board

Share This Post

News Release

Release Date: 08/09/2019
Staff Reference: Kevin Dorse

CLHIA

Staff Reference: Kevin Dorse

(Toronto, August 9, 2019) – The Canadian Life and Health Insurance Association (CLHIA) welcomes today’s final amendments to the Patented Medicine Prices Review Board (PMPRB) regulations as a crucial step to lower prescription drug costs for all Canadians.

“The changes announced today will mean lower costs for prescription medicines whether they are provided by governments or through workplace plans offered by employers to 25 million Canadians,” Stephen Frank, President and CEO of the CLHIA said. “This modernization is good news for all Canadians who are currently paying some of the highest drug prices in the world.”

Recent Posts

Categories

Archives

Related Post

Spring Breakfast Education Session

Thank you to all those that attended our Spring Breakfast Education Session  . . .  we hope that you enjoyed it as much as we

Send A Message to David Rojas